Literature DB >> 12020867

Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury.

Weiya Ma1, Wei Du, James C Eisenach.   

Abstract

The effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs) in treating neuropathic pain caused by nerve injury has been controversial. In the present study, 4 weeks following partial sciatic nerve ligation, a single intrathecal injection of the cyclooxygenase (COX)-1 preferring inhibitor ketorolac (50 microg) significantly attenuated tactile allodynia for 6 days. The COX-2 preferring inhibitor, NS-398 (60 microg) significantly reversed tactile allodynia 2 h following injection but this anti-allodynic effect did not last greater than 24 h. Surprisingly, the non-selective COX inhibitor, piroxicam (60 microg) was without effect. These data agree with previous studies suggesting that spinal prostaglandin synthesis is important in the maintenance of hypersensitivity states following nerve injury. They differ from results in other models by suggesting that both COX isoenzymes are important in this spinal process, and for the first time demonstrate a remarkably long duration of action from a single intrathecal injection of ketorolac. Inhibition of spinal COX may be an important mechanism of action in treating some patients with neuropathic pain following peripheral nerve injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020867     DOI: 10.1016/s0006-8993(02)02593-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

1.  The anti-arthritic and anti-oxidative effect of NBD (6-nitro-1,3-benzodioxane) in adjuvant-induced arthritis (AIA) in rats.

Authors:  Syed Uzair Ali Shah; Nadeem Ashraf; Zahid H Soomro; Muhammad Raza Shah; Nurul Kabir; Shabana Usman Simjee
Journal:  Inflamm Res       Date:  2012-04-27       Impact factor: 4.575

2.  The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy.

Authors:  Flobert Y Tanga; Nancy Nutile-McMenemy; Joyce A DeLeo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

3.  Host-pathogen interactions mediating pain of urinary tract infection.

Authors:  Charles N Rudick; Benjamin K Billips; Vladimir I Pavlov; Ryan E Yaggie; Anthony J Schaeffer; David J Klumpp
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

4.  Tenoxicam modulates antioxidant redox system and lipid peroxidation in rat brain.

Authors:  Mustafa Naziroğlu; Abdulhadi Cihangir Uğuz; Alpaslan Gokçimen; Metin Bülbül; Dilek Ulusoy Karatopuk; Yasin Türker; Celal Cerçi
Journal:  Neurochem Res       Date:  2008-03-14       Impact factor: 3.996

Review 5.  TNF-alpha and neuropathic pain--a review.

Authors:  Lawrence Leung; Catherine M Cahill
Journal:  J Neuroinflammation       Date:  2010-04-16       Impact factor: 8.322

6.  Recent advances in the treatment of pain.

Authors:  Mellar P Davis
Journal:  F1000 Med Rep       Date:  2010-08-19

7.  Constitutive cyclooxygenase-2 is involved in central nociceptive processes in humans.

Authors:  Frédéric Martin; Dominique Fletcher; Marcel Chauvin; Didier Bouhassira
Journal:  Anesthesiology       Date:  2007-05       Impact factor: 7.892

8.  Ketorolac reduces spinal astrocytic activation and PAR1 expression associated with attenuation of pain after facet joint injury.

Authors:  Ling Dong; Jenell R Smith; Beth A Winkelstein
Journal:  J Neurotrauma       Date:  2013-05-06       Impact factor: 5.269

9.  Pre-treatment with Meloxicam Prevents the Spinal Inflammation and Oxidative Stress in DRG Neurons that Accompany Painful Cervical Radiculopathy.

Authors:  Sonia Kartha; Christine L Weisshaar; Blythe H Philips; Beth A Winkelstein
Journal:  Neuroscience       Date:  2018-08-04       Impact factor: 3.590

10.  A Selective Role for alpha3 Subunit Glycine Receptors in Inflammatory Pain.

Authors:  Victoria L Harvey; Alex Caley; Ulrike C Müller; Robert J Harvey; Anthony H Dickenson
Journal:  Front Mol Neurosci       Date:  2009-11-04       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.